US to Buy IV Drug to Help With Monkeypox Outbreak
The United States will buy $26 million worth of the intravenous (IV) version of TPOXX, an antiviral drug, to treat monkeypox, according to the drug's manufacturer, SIGA Technologies, Inc.
Expanded access: The oral and IV versions of TPOXX are approved for the treatment of smallpox but not for monkeypox yet. The Centers for Disease Control and Prevention has provided guidance for use under "expanded access" as an experimental drug.
Important option: The IV version of the drug is an important option for patients who cannot swallow the pill version because of the oral rashes and blisters that monkeypox can cause.
When: The product will be delivered in 2023.
The contract and funding of a study for IV TPOXX "highlight the growing importance of a broad-based response to the substantial risks posed by the orthopox family of viruses, including smallpox and monkeypox," said Phil Gomez, PhD, CEO of SIGA.
More Evidence That Salt Substitutes Lower Risk for CVD and Death
Dietary salt substitutes not only lower blood pressure but also lower risk for myocardial infarction, stroke, cardiovascular disease (CVD), and death, according to a new meta-analysis.
What they do:Salt substitutes replace a proportion of sodium chloride with
